An experimental therapy may change the way prostate cancer patients are treated. In a landmark clinical trial, presented at the European Society of Medical Oncology conference in Barcelona, the drug olaparib was shown to be safe and effective in delaying the progression of disease in men. Olaparib is sold under the brand name Lynparza and works by targeting and killing cancer cells. The trial involved administering olaparib to over 380 patients. The findings suggest that olaparib may be beneficial in the treatment of patients with metastatic hormone-resistant prostate cancer.